IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

BACKGROUND: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. METHODS: 120 patients treated...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Di Salvatore, Mariantonietta, Pietrantonio, Filippo, Orlandi, Armando, Del Re, Marzia, Berenato, Rosa, Rossi, Ernesto, Caporale, Marta, Guarino, Donatella, Martinetti, Antonia, Basso, Michele, Mennitto, Roberta, Santonocito, Concetta, Mennitto, Alessia, Schinzari, Giovanni, Bossi, Ilaria, Capoluongo, Ettore, Danesi, Romano, de Braud, Filippo, Barone, Carlo
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370008/
https://ncbi.nlm.nih.gov/pubmed/28129643
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14810
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados